mRNA处于十字路口：政策不确定性威胁革命性医学突破-动脉网

mRNA at a Crossroads: Transformative Medical Breakthroughs Threatened by Policy Uncertainty

CISION 等信源发布 2025-05-08 21:00



可切换为仅中文







Experts warn that weakening mRNA support could create a domino effect—undermining America's scientific leadership, diminishing bioeconomic competitiveness, and compromising national security and pandemic preparedness

专家警告说，削弱对mRNA的支持可能会产生多米诺骨牌效应——削弱美国的科学领导地位，降低生物经济竞争力，并损害国家安全和大流行病的应对准备。

WASHINGTON

华盛顿

，

May 8, 2025

2025年5月8日

/PRNewswire/ -- A survey released today from the Alliance for mRNA Medicines warns that cuts to biomedical research and threats of anti-mRNA policies risk delays to therapeutic advances in cancer, rare diseases, and other diseases, loss of billions in potential healthcare savings, and place US biomedical leadership and national security in the hands of other countries.

/PRNewswire/ -- mRNA药物联盟今天发布的一项调查警告称，削减生物医学研究资金以及反对mRNA政策的威胁，可能延缓癌症、罕见病及其他疾病治疗的进步，导致潜在数千亿美元医疗节省的损失，并将美国生物医学的领导地位和国家安全交到其他国家手中。

In the survey, 81% of industry leaders expressed concern that anti-mRNA policies would cause manufacturing, research, and related jobs to leave the U.S. in favor of pro-innovation environments in .

在调查中，81%的行业领袖表示担心反mRNA政策会导致制造业、研究及相关工作岗位离开美国，转向支持创新的环境。

Europe

欧洲

and

和

Asia

亚洲

。

Once hailed as the cornerstone of pandemic response, mRNA is now evolving into a revolutionary therapeutic platform poised to reshape modern medicine—if supported by strategic policy and sustained investment. Recent research highlights mRNA's transition from a vaccine platform into a versatile therapeutic engine, enabling personalized cancer immunotherapies, targeted therapies for rare genetic diseases and chronic illnesses, and rapid responses to infectious diseases.

曾经被誉为应对疫情的基石，mRNA如今正逐渐演变为一个革命性的治疗平台，有望重塑现代医学——只要得到战略性政策的支持和持续的投资。最近的研究强调了mRNA从疫苗平台向多功能治疗引擎的转变，使个性化癌症免疫疗法、针对罕见遗传疾病和慢性病的靶向治疗以及对传染病的快速反应成为可能。

Breakthroughs in on-site manufacturing, delivery mechanisms, and next-generation RNA architectures are accelerating this revolution..

现场制造、递送机制和下一代 RNA 架构的突破正在加速这场革命。

'The U.S. has led the world in the discovery and development of mRNA products and catalyzed a sector that will transform the future of medicine. Unfortunately, today, anti-mRNA policies, including funding cuts at the National Institutes of Health, threaten U.S. manufacturing and research jobs as well as the opportunity to address the unmet needs of those living with cancer and rare diseases,' said .

“美国在mRNA产品的发现和开发方面处于世界领先地位，并催化了一个将改变医学未来的领域。然而，不幸的是，如今包括美国国家卫生研究院资金削减在内的反mRNA政策，正威胁着美国的制造业和科研岗位，同时也威胁到满足癌症及罕见病患者未满足需求的机会，”他说。

Clay Alspach

克莱·阿尔斯帕赫

, Executive Director, Alliance for mRNA Medicines. 'With appropriate policy support and investment, mRNA can deliver innovative and lower cost therapies for patients with unmet needs and enhance national security preparedness. US policymakers should seize this opportunity to help patients, create jobs, lower costs, and protect the country.'.

执行董事，mRNA药物联盟。 “在适当的政策支持和投资下，mRNA可以为有未满足需求的患者提供创新且成本更低的治疗方法，并增强国家安全准备。美国政策制定者应抓住这一机会，帮助患者，创造就业机会，降低成本，并保护国家。”

The survey provides a timely assessment of the impacts of policies that are proposed and, in some cases, already implemented like funding disruptions and anti-mRNA policy developments. Key findings of the survey include:

该调查及时评估了所提议政策的影响，在某些情况下，这些政策已经实施，如资金中断和反mRNA政策的发展。调查的主要发现包括：

48% of surveyed mRNA organizations have already experienced direct impacts from recent policy disruptions and funding cuts

48%的受访mRNA组织已经受到近期政策变动和资金削减的直接影响。

. Those impacts include:

。这些影响包括：

54% were forced to cut back on mRNA R&D and postponed studies

54% 被迫削减mRNA研发并推迟研究

46% experienced budget freezes and reductions

46% 的人经历了预算冻结和削减

46% cancelled collaborations

46% 取消了合作

46% delayed capital investments

46% 延迟的资本投资

30% initiated hiring freezes or layoffs among specialized scientific personnel

30% 的机构开始冻结招聘或裁减专业科学人员

20% are relocating projects, divisions or entire company, particularly moving from the U.S. to

20%正在重新安置项目、部门或整个公司，特别是从美国搬迁到

Europe

欧洲

或

Asia

亚洲

66% of mRNA-related jobs are located in the U.S

66%的mRNA相关工作岗位位于美国。

. and up to

。以及高达

45% of those U.S. positions

美国这些职位的45%

are potentially at risk, with

潜在地面临风险，伴随着

21%

of organizations indicating

组织表明

all

全部

such U.S. roles could be eliminated under hostile policy conditions, based on survey results.

根据调查结果，在敌对政策条件下，这些美国角色可能会被消除。

According to

根据

Andy Geall

安迪·吉尔

, PhD, Chief Development Officer at Replicate Bioscience and Chair of the Board of the Alliance for mRNA Medicines, 'The report is clear: by retreating from mRNA,

，博士，Replicate Bioscience首席开发官兼mRNA药物联盟董事会主席，“报告明确指出：通过放弃mRNA，

the United States

美国

risks losing an entire generation of innovation and intellectual capital.' Geall continued, 'This would transform

有可能失去整整一代的创新和智力资本。' Geall继续说道，'这将转变

the United States

美国

from the mRNA leader to one reliant on the rest of the world for biomedical advances.'

从mRNA领导者转变为依赖世界其他国家进行生物医学进步。

Respondents identified that a pro-mRNA agenda should include increased investment and regulatory clarity – advancing mRNA's therapeutic potential while accelerating next-generation solutions across three core domains: personalized cancer immunotherapies, rare disease treatments, and infectious disease prevention..

受访者指出，推动mRNA发展的议程应包括加大投资和监管清晰度——在推进mRNA治疗潜力的同时，加速在三个核心领域的下一代解决方案：个性化癌症免疫疗法、罕见病治疗和传染病预防。

As the global race for biotech leadership intensifies, policy decisions made today will determine whether

随着全球生物技术领导地位的竞争加剧，今天做出的政策决定将决定是否

the United States

美国

continues to lead or becomes reliant on foreign advances. Experts urge Congress and federal agencies to act now—preserving America's hard-won momentum and securing the health, security, and prosperity of future generations.

继续领先或依赖外国的进步。专家们敦促国会和联邦机构立即采取行动——保持美国来之不易的发展势头，并确保子孙后代的健康、安全和繁荣。

About the Survey

关于调查

The survey for 'The mRNA Innovation Ecosystem (U.S.): 2025 Assessment of Economic Impact, Therapeutic Potential & Policy Implications' was commissioned in March and

《mRNA创新生态系统（美国）：2025年经济影响、治疗潜力与政策影响评估》的调查于三月委托进行，

April 2025

2025年4月

by the Alliance for mRNA Medicines. It gathered insights from 106 senior leaders across biopharma, pharmaceuticals, contract manufacturing organizations, life science technology firms and academic research institutions, with the majority having over a decade of industry experience. A summary and the full report can be found here: .

由mRNA药物联盟提供。它汇集了来自生物制药、制药、合同制造组织、生命科学技术公司和学术研究机构的106名高级领导的见解，其中大多数人拥有超过十年的行业经验。总结和完整报告可以在这里找到：。

https://mrnamedicines.org

。

Alliance for mRNA Medicines (AMM)

mRNA药物联盟（AMM）

The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients' lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.

信使RNA药物联盟（AMM）是全球领先的组织，致力于推动和倡导信使RNA及下一代编码RNA治疗药物和疫苗的发展，以造福患者、公共卫生和社会。我们的使命是通过汇聚和赋能信使RNA行业的领导者、创新者、科学家以及其他关键利益相关者，推动信使RNA医学的未来，改善患者生活，并促进科学知识的进步。

Learn more at .

了解更多，请访问。

https://mrnamedicines.org

Media Contact:

媒体联系人：

Clay Alspach

克莱·阿尔斯帕

Executive Director

执行董事

Alliance for mRNA Medicines

mRNA药物联盟